Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
SABSW
SABSW
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SABSW News
SAB Bio Reveals New Clinical and Mechanistic Findings from SAB-142 Phase 1 Trial in Adults with Established Autoimmune Type 1 Diabetes at IDS 2026
Apr 22 2026
moomoo
SAB BIO Announces Financial Results for Third Quarter and Key Business Updates
Nov 13 2025
Newsfilter
SAB BIO Showcases Data Through Various Presentations at EASD
Sep 19 2025
Newsfilter
SAB BIO Announces Oversubscribed $175 Million Private Placement
Jul 21 2025
Newsfilter
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
May 09 2025
Newsfilter
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
Nov 06 2024
Newsfilter
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
Oct 31 2024
Newsfilter
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
Sep 09 2024
Newsfilter
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
Sep 04 2024
Newsfilter
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
Aug 08 2024
Newsfilter
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
Aug 05 2024
Newsfilter
SAB BIO Appoints Lucy To as Chief Financial Officer
Jul 31 2024
Newsfilter
SAb Biotherapeutics Rebrands as SAB BIO
Jun 20 2024
Newsfilter
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
Jun 18 2024
Newsfilter
SAB Biotherapeutics Announces Departure of Chief Financial Officer
May 30 2024
newsfilter
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
May 21 2024
newsfilter
Show More News
